News | June 11, 2008

Cook's Drug-Eluting Peripheral Stent Shows Promising Preliminary Results

June 12, 2008 – The registry arm of a clinical study to assess the safety and effectiveness of Cook Medical’s Zilver PTX Drug-Eluting Peripheral Stent (DES) in treating peripheral arterial disease (PAD) has yielded positive interim results, trial investigators reported at the 2008 SVS Vascular Annual Meeting last week.

The findings, presented by Michael Dake, M.D., professor of Radiology, Internal Medicine and Surgery and chairman of the Department of Radiology at the University of Virginia Health System, reveal clinical improvement, excellent stent durability (i.e., fracture resistance), high rates of event-free survival (EFS) and freedom from target lesion revascularization (TLR). This preliminary information suggests no safety concerns, and promising effectiveness results.

“Cook's registry study and randomized trial are the first to use a paclitaxel-coated stent in the treatment of arterial blockages outside the heart,” said Dr. Dake, the trial’s global principal investigator. “They are designed to evaluate the safety and effectiveness of DES technology versus percutaneous transluminal angioplasty, and our initial findings in the registry arm give us every reason to believe that Zilver PTX may have the integrity, safety and durability needed to successfully address many of the well-known limitations of angioplasty alone for management of PAD.”

Interim data were compiled at six and 12 months for 435 patients and 200 patients respectively from the registry study, which enrolled a broad spectrum of patients, including those with complex lesions (e.g., long lesions, total occlusions, in-stent restenosis). The corresponding EFS rates were 94 percent and 84 percent, and freedom from TLR was 96 percent and 88 percent. Clinical measures that included ankle-brachial index, Rutherford score, and walking distance and speed scores showed significant improvement at six months and was maintained through 12 months.

Evaluation of stent x-rays is ongoing, and currently suggests stent fractures in only about one percent of cases at six months and less than two percent of cases at 12 months. Follow-up in the registry arm of the study will continue through two years.

“We are quite pleased with this first round of data from the registry portion of the study, and are optimistic we’ll encounter similar results throughout the duration of the Zilver PTX trial,” said Rob Lyles, global leader of Cook Medical's Peripheral Intervention products division. “At Cook, we are continually driving to improve the quality of our products and, in turn, improve the quality of patient outcomes. We are particularly excited about the potential benefits our self-expanding Zilver PTX stent provide can patients suffering from PAD.”

The clinical study is designed to evaluate the Zilver PTX in more than 1,000 patients across 89 trial sites in the United States, Asia, Latin America, Canada and Europe. In addition to the 790 DES patients enrolled in the registry arm of the study, approximately 240 of the 480 patients to be enrolled in the randomized arm of the study will receive the DES. Follow-up is ongoing for the registry, while enrollment in the randomized study is expected to be complete within the coming months.

For more information, visit www.cookmedical.com and www.zilverptxtrial.com

Related Content

Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Biosensors, BioFreedom drug-coated stent, LEADERS FREE II IDE trial, first patient, U.S. pivotal study
News | Stents Drug Eluting| March 03, 2017
Biosensors International Group Ltd. announced in February enrollment of the first patient in LEADERS FREE II, its new...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents| January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
Overlay Init